Insulin-like growth factor 1 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-30. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
质量控制项目一般包括外观、身份、纯度、含量、有关物质、水分和微生物限度。身份确认可通过肽图谱、氨基酸分析和质谱完成，纯度则用面积归一化法计算。研究级材料与药品级材料的要求不同，前者常缺少完整药典验证。不同批次间杂质谱是否影响活性，仍是一个需要具体数据回答的问题。
特沙莫瑞林的检测通常依赖反相高效液相色谱和质谱联用。反相色谱可分离肽主峰与缺失序列、氧化产物等杂质，质谱则提供精确质量以确认身份。对于复杂基质中的定量，常采用液相色谱-串联质谱，并配合固相萃取或蛋白沉淀。生物样品中的肽易降解，因此采集和处理条件会影响结果。
=== Sales and usage === Sales of bicalutamide (as Casodex) worldwide peaked at US$1.3 billion in 2007, and it has been described as a "billion-dollar-a-year" drug prior to losing its patent protection starting in 2007. In 2014, despite the introduction of abiraterone acetate in 2011 and enzalutamide in 2012, bicalutamide was still the most commonly prescribed drug in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Moreover, in spite of being off-patent, bicalutamide was said to still generate a few hundred million dollars in sales per year for AstraZeneca. Total worldwide sales of brand name Casodex were approximately US$13.4 billion as of the end of 2018.
== Synthesis and reactions == Industrially, L-serine is produced from glycine and methanol catalyzed by hydroxymethyltransferase. Racemic serine can be prepared in the laboratory from methyl acrylate in several steps:
United States The new 323 arrived in the United States for the 1986 model year and continued to be available through 1989. The naming practice was now aligned with most of Mazda's export markets, with the 323 badge replacing GLC. For 1987 the wagon version was added to the lineup, with the same mechanicals as the hatchbacks and saloons. In 1988, Mazda added a turbocharged option in the GT and GTX model as well as four-wheel drive in the GTX model. The GTX was the first four-wheel drive passenger car Mazda offered in the United States. The GT and GTX featured a turbocharged and intercooled 1.6 liter 16-valve DOHC 4-cylinder engine rated at 132 hp (98 kW) and only was available with a 5-speed manual transmission.
== Structure == The 5-HT3 receptor differs markedly in structure and mechanism from the other 5-HT receptor subtypes, which are all G-protein-coupled. A functional channel may be composed of five identical 5-HT3A subunits (homopentameric) or a mixture of 5-HT3A and one of the other four 5-HT3B, 5-HT3C, 5-HT3D, or 5-HT3E subunits (heteropentameric). It appears that only the 5-HT3A subunits form functional homopentameric channels. All other subunit subtypes must heteropentamerize with 5-HT3A subunits to form functional channels. Additionally, there has not currently been any pharmacological difference found between the heteromeric 5-HT3AC, 5-HT3AD, 5-HT3AE, and the homomeric 5-HT3A receptor. N-terminal glycosylation of receptor subunits is critical for subunit assembly and plasma membrane trafficking. The subunits surround a central ion channel in a pseudo-symmetric manner (Fig.1). Each subunit comprises an extracellular N-terminal domain which comprises the orthosteric ligand-binding site; a transmembrane domain consisting of four interconnected alpha helices (M1-M4), with the extracellular M2-M3 loop involved in the gating mechanism; a large cytoplasmic domain between M3 and M4 involved in receptor trafficking and regulation; and a short extracellular C-terminus (Fig.1). Whereas extracellular domain is the site of action of agonists and competitive antagonists, the transmembrane domain contains the central ion pore, receptor gate, and principle selectivity filter that allows ions to cross the cell membrane.
Sources: en.wikipedia.org
=== International === Foreign governments said little in the days after the vote, most of them waiting for parliament to choose a prime minister. Once Anutin was returned to office on 19 March, United States Secretary of State Marco Rubio congratulated him and said the United States valued an alliance and friendship with Thailand spanning nearly two centuries, singling out law enforcement cooperation against cyber-scam networks and the modernisation of the defence relationship. Malaysian Prime Minister Anwar Ibrahim described Anutin as a "dear friend" and wrote that the two countries' "fates are like two rivers born of the same spring", pointing to trade, investment and cooperation along the border. Indian Prime Minister Narendra Modi followed the next day, saying that he looked forward to deepening the India-Thailand strategic partnership.
All CHO cell lines are deficient in proline synthesis. Also, CHO cells do not express the epidermal growth factor receptor (EGFR), which makes them ideal in the investigation of various EGFR mutations. Furthermore, Chinese hamster ovary cells are able to produce proteins with complex glycosylations, post-translational modifications (PTMs) similar to those produced in humans. They are easily growable in large-scale cultures and have great viability, which is why they are ideal for GMP protein production. Also, CHO cells are tolerant to variations in parameters, be it oxygen levels, pH-value, temperature or cell density. Having a very low chromosome number (2n=22) for a mammal, the Chinese hamster is also a good model for radiation cytogenetics and tissue culture. Being the first cell line to be used for recombinant pharmaceutical production, regulatory concerns were raised with respect to Endogenous Retroviral Sequences (ERS). CHO cells contain about 1000 of these sequences and some of them are able to direct the synthesis of Intracisternal A-type particles and C-type particles. Also, low expression of reverse transcriptase was observed. However the majority of ERS are defective (stop codons in all reading frames) and contain large deletions of a putative retroviral genome.
In contrast to organomagnesium compounds, organocalcium compounds are not similarly useful, with one major exception, calcium carbide, CaC2. This material, which has historic significance, is prepared by heating calcium oxide with carbon. According to X-ray crystallography, calcium carbide can be described as Ca2+ derivative of acetylide, C22-, although it is not a salt. Several million tons of calcium carbide are produced annually. Hydrolysis gives acetylene, which is used in welding and a chemical precursor. Reaction with nitrogen gas converts calcium carbide to calcium cyanamide. A dominant theme in molecular organocalcium chemistry is the large radius of calcium, which often leads to high coordination numbers. For example, dimethylcalcium appears to be a 3-dimensional polymer, whereas dimethylmagnesium is a linear polymer with tetrahedral Mg centers. Bulky ligands are often required to disfavor polymeric species. For example, calcium dicyclopentadienyl, Ca(C5H5)2 has a polymeric structure and thus is nonvolatile and insoluble in solvents. Replacing the C5H5 ligand with the bulkier C5(CH3)5 (pentamethylcyclopentadienyl) gives a soluble complex that sublimes and forms well-defined adducts with ethers. Organocalcium compounds tend to be more similar to organoytterbium compounds due to the similar ionic radii of Yb2+ (102 pm) and Ca2+ (100 pm). Organocalcium compounds have been well investigated. Some such complexes exhibit catalytic properties, although none have been commercialized.
== Side effects == Potential side effects of 5-HTP include heartburn, abdominal pain, nausea, vomiting, diarrhea, drowsiness, sexual problems, vivid dreams or nightmares, and muscle problems. Serotonin syndrome can occur. Because 5-HTP has not been thoroughly studied in a clinical setting, possible side effects and interactions with other drugs are not well known. According to the US National Library of Medicine, 5-HTP has not been associated with serotonin syndrome or any serious adverse events in humans. Across multiple studies, 5-HTP has also been reported to not cause any noticeable hematological or cardiovascular changes. 5-HTP had also been associated with eosinophilia, but later studies have not found any causal connection.
Shortly after the start of the crisis, the Danish Realm began rapidly expanding its military capabilities in the Arctic. On 27 January 2025, its governments agreed to the First Agreement on the Arctic and North Atlantic, which invested a total of kr. 14.6 billion (US$2.05 billion) into warning systems in the Faroe Islands and Greenland, new naval vessels, drone warfare training, a new radiation monitoring station in East Greenland, upgrades to the Joint Arctic Command in Nuuk and intelligence, satellite surveillance, two new coastal radars, and Arctic basic military training in Kangerlussuaq. This was followed by the Second Agreement on 10 October 2025, providing upgrades worth kr. 27.4 billion (US$4.26 billion) for improvements of what was presented in the First Agreement, alongside upgrades to Kangerlussuaq Airport, a new specialised Arctic unit under the Jaeger Corps of the Special Operations Command that could operate anywhere in Greenland, establishment of radar capability in East Greenland, establishment of a Greenlandic reconnaissance Unit, and the construction of a new undersea cable connecting Greenland to mainland Denmark. In summer 2025, the Greenlandic government and the Danish Defence both announced that Greenland would have increased military presence by September, as part of Operation Arctic Light. On 18 August 2025, the Ministry of Justice allocated a package worth more than kr. 850 million to their operations in Greenland and the Faroe Islands.
Sources: en.wikipedia.org
Domino's Pizza, Inc., trading as Domino's, is an American multinational pizza restaurant chain founded in 1960. The corporation is Delaware-domiciled and headquartered at the Domino's Farms office park in Ann Arbor Township near Ann Arbor, Michigan. As of 2018, Domino's had approximately 15,000 stores, with 5,649 in the United States, 1,500 in India, and 1,249 in the United Kingdom. Domino's has stores in more than 83 countries and 5,701 cities worldwide.
Hsp20 also serves a significant role in preventing platelet aggregation, cardiac myocyte function and prevention of apoptosis after ischemic injury, and skeletal muscle function and muscle insulin response. Hsp27 is a major phosphoprotein during women's contractions. Hsp27 functions in small muscle migrations and appears to serve an integral role.
Groups may undergo quarantine, or in the case of communities, a cordon sanitaire may be imposed to prevent infection from spreading beyond the community, or in the case of protective sequestration, into a community. Public health authorities may implement other forms of social distancing, such as school closings, lockdowns or temporary restrictions (e.g. circuit breakers) to control an epidemic.
GLUTs are integral membrane proteins composed of 12 α-helix membrane spanning regions. The GLUT proteins are encoded by the SLC2 genes and categorized into three classes based on amino acid sequence similarity. Humans have been found to express fourteen GLUT proteins. Class I GLUTs include GLUT1, one of the most studied isoforms, and GLUT2. GLUT1 is found in various tissues like the red blood cells, brain, and blood-brain barrier and is responsible for basal glucose uptake. GLUT2 is predominantly found in the liver, pancreas, and small intestines. It plays an important role in insulin secretion from pancreatic beta cells. Class II includes the GLUT3 and GLUT4. GLUT3, primarily found in the brain, neurons and placenta, has a high affinity for glucose in facilitating glucose uptake into neurons. GLUT4 plays a role in insulin-regulated glucose uptake and is mainly found in insulin-sensitive tissues such as muscle and adipose tissue. Class III includes GLUT5, found in the small intestine, kidney, testes, and skeletal muscle. Unlike the other GLUTs, GLUT5 specifically transports fructose rather than glucose. Glucose transporters allow glucose molecules to move down their concentration gradient from areas of high glucose concentration to areas of low concentration. This process often involves bringing glucose from the extracellular space or blood into the cell. The concentration gradient set up by glucose concentrations fuels the process without the need for ATP.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.